Dr. Juan P. Frías
Biography & Research Background
Juan P. Frías, MD, is a principal investigator at Velocity Clinical Research in Los Angeles, CA. Dr. Frías has been a lead investigator across the SURPASS clinical trial program for type 2 diabetes. He was the lead author on the landmark SURPASS-2 trial published in the New England Journal of research compound, which demonstrated tirzepatide’s superiority over semaglutide in both HbA1c reduction and weight loss. He also led early Phase 2 dose-finding studies that established the clinical proof of concept for dual GIP/GLP-1 receptor agonism. Juan P. Frías is being referenced as one of the leading scientists involved in the research and development of GLP-2 Analog (Teduglutide). In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor.
External Profiles
Authored Research Profiles (1)
Dr. Juan P. Frías is referenced as a leading researcher in the following peptide research profiles on Pure U.S. Peptides:
Dr. Juan P. Frías is being referenced as one of the leading scientists involved in the research and development of the peptides listed above. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of any product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure U.S. Peptides and this researcher. The purpose of citing the researcher is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying these peptides.